Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Habermann, Thomas M  [Clear All Filters]
2024
Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024.
Arcaini L, Bommier C, Alderuccio JPablo, Merli M, Fabbri N, Nizzoli MElena, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, et al. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024;72:102592.
2022
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JVillasboas, Rosenthal A, et al. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022.
Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9(4):e289-e300.
2021
Herrmann J, McCullough K, Habermann TM. How I treat cardiovascular complications in patients with lymphoid malignancies. Blood. 2021.
Khurana A, Hathcock M, Habermann TM, Saleh AAl, Gandhi S, Truong T, N Bennani N, Paludo J, Villasboas JC, Ansell SM, et al. Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma. Am J Hematol. 2021.